ETICS

Evolved Tissue Inspired Cell Systems

ETICS est accrédité par Lyonbiopôle

Identity card

Global budget: 14400 k€

Public funding: 7600 k€

Public funders: ANR, Agence Nationale de la Recherche, European Commission, Oséo / BPI France (except FUI)

Call for projects: ISI Oséo

Year start: 2011

Completed project (2017-08)


Accredited by the French competitiveness cluster Lyonbiopôle


Strategic business area: Human Medicines, Therapeutics, active ingregrients & nutraceuticals

Application fields: Dermocosmetics, Genetic / Rare diseases, Nutrition / Food, Oncology, Orphan diseases, Muscular diseases

Technological approaches / Keywords: Cell model / Animal model, Functional Screening / Drug discovery

Stage of development at the beginning of the project: Basic research

Abstract

The use of relevant cellular models in drug discovery programs would considerably improve the identification of valuable drug candidates, i.e. molecules with high efficacy and low toxicity. However, conversion to such models represents a huge challenge as it is usually badly adapted to large scale screening constraints. The ETICS program aims at addressing these bottlenecks by exploiting the benefits of micropattern technology on cellular models: improved maturation, higher functionality and reduced variability. Combined with the use of human primary cells, such approach offer new opportunities to develop innovative screening strategies leading to the identification of more potent drug candidates.


Objectives

ETICS aims to establish new cellular models and screening strategies adapted to large scale drug discovery programs for the skin and muscle. It will also provide innovative assays to address compounds safety with a particular focus on renal and hepatotoxicity. To achieve these goals, we will develop cellular models and assays that are more physiologically relevant as well as better suited for high content imaging and analysis (HCA) than conventional methods by combining the use of human primary cells with micropattern technology.


Innovative assets
Highlights
Actual results
Perspectives

Innovative assets

The innovative asset of the ETICS project relies on the synergistic combination of: -       - The development of dedicated micropattern allowing the establishment of novel cellular models with improved maturation, higher functionality, reduced variability and compatibility with High Content Screening -       - The use of human primary cells which represent highly relevant models -       - The selection of cellular systems for which no human in vitro models are currently available (muscle) or are poorly compatible with large scale screening (microepidermis) -       - The direct compatibility with Phenotypic Screening approaches which are known to provide higher translational potential and clinical use of drug candidates

En poursuivant votre navigation sur notre site, vous acceptez l'utilisation des cookies et la collecte de vos données et informations personnelles par Lyonbiopôle, dans les finalités de mesurer le trafic sur le site Web, de fournir des statistiques et de vous proposer des contenus adaptés à vos centres d’intérets. Pour exercer vos droits d'accès, de rectification, d'opposition, de suppression et de portabilité, conformément au règlement général sur la protection des données (UE n°2016/679), vous etes informés que vous pouvez envoyer votre demande à dpo@lyonbiopole.com. Plus de détails sont disponibles en cliquant ici J'accepte